The first such production in Central Asia is estimated at $250 million.
Xindeyuan Bioengineering plans to set up a blood products plant in Uzbekistan, the press service of the Health Ministry reported.
Representatives of the Ministry a few days ago held talks with a delegation from a Chinese company. The parties agreed on the implementation of the project of a pharmaceutical complex in the Samarkand region.
The plant will be located on a plot of 15 hectares in the FEZ "Urgut". Xindeyuan Bioengineering plans to invest $250 million in it.
The future enterprise for the production of hematological drugs and reagents will be the first in Central Asia. Its launch will cover the needs of the population in blood components and related products, as well as reduce their import.
As noted in the Ministry of Health, 67 types of medicines and medical devices are now used in hematology and transfusiology. However, they are mostly shipped from abroad.
